Literature DB >> 2642778

Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism.

W M Awni1, B L Kasiske, K Heim-Duthoy, K V Rao.   

Abstract

Sequential changes in the pharmacokinetics of cyclosporine (CsA) and metabolites M1, M17, and M21 were determined, 1, 3, and 12 weeks after initiation of CsA therapy in 21 renal transplant recipients. Concentrations of CsA and its metabolites were measured by HPLC. The dose-adjusted AUC (AUCSS tau) and 24-hour trough (C24trough) level of CsA and the metabolites increased significantly during the study period. However, there was no change in the AUCSS tau ratio of each of the metabolites to that of CsA, suggesting that CsA metabolism did not change. However, the factors that alter the binding and distribution of CsA (i.e., hematocrit, plasma proteins, and lipoproteins) showed a significant rise during the study period, and the rise correlated well with the observed changes in AUCSS tau and C24trough. Thus alterations in the distribution and binding of CsA and its metabolites in blood, rather than reduction in the metabolism of CsA, may explain changes in CsA pharmacokinetics over time.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642778     DOI: 10.1038/clpt.1989.7

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  The binding of cyclosporin A to human plasma: an in vitro microdialysis study.

Authors:  H Yang; W F Elmquist
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

5.  Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study.

Authors:  Xiaochun Wu; Qing Li; Huawen Xin; Airong Yu; Mingyuan Zhong
Journal:  Eur J Clin Pharmacol       Date:  2005-08-26       Impact factor: 2.953

6.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

7.  Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; J Grevel; P W Lücker; K Kutz
Journal:  Pharm Res       Date:  1994-01       Impact factor: 4.200

8.  Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

Authors:  J M Tredger; J Grevel; N Naoumov; C M Steward; A A Niven; B Whiting; R Williams
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

Authors:  T L Schwinghammer; D Przepiorka; R Venkataramanan; C P Wang; G J Burckart; C S Rosenfeld; R K Shadduck
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

10.  The preparation and evaluation of a tablet dosage form of cyclosporine in dogs.

Authors:  H Y Abdallah; M Mayersohn
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.